Investment View (over the next 12 months) - PTD has encouraging medium-term prospects. After a steep share price decline from Nov-04, PTD has again found investor support since mid May-05. Biotechnology sector sentiment is still poor in Australia and we expect price volatility for PTD to continue. However, US sentiment to the biotech sector has improved considerably over the past few months and we anticipate that a favourable flow-on effect will be felt in our market before the end of the year. We re-instate a BUY recommendation on PTD.
- Forums
- ASX - By Stock
- PTD
- ageis comment
PTD
unknown
ageis comment
Featured News
Add PTD (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online